Lucerne Biosciences Engages as "Third-Party Intermediary" to Handle Sensitive Information from the Public Regarding "The Patent '813 Story"

Mar 11, 2016, 07:00 ET from Lucerne Biosciences, LLC

NEW HAVEN, Conn., March 11, 2016 /PRNewswire/ -- Lucerne Biosciences, LLC announced today that it has engaged "" to act as a "third-party intermediary" for handling sensitive information from the public related to "The Patent '813 Story" across its broad multi-party communications platform. This "third-party intermediary role" between the company and the public has emerged from providing the company important whistleblower information from multiple venues, certain details of which are featured in the latest version of "The Patent '813 Story, Part II"  (see references below).   On June 4, 2015 Lucerne Biosciences' wholly owned U.S. Patent 8,318,813 (the '813 Patent), which claimed methods for the treatment of Binge Eating Disorder by Shire's drug Vyvanse® (lisdexamfetamine dimesylate), was invalidated by the U.S. Patent Trial & Appeal Board based on an Inter Partes Review (IPR) proceeding initiated by Shire Development LLC.  Shire's IPR behavior has been extensively evaluated for anti-competitive conduct and deceptive trade practice.

Lucerne Biosciences' Manager Louis C. Sanfilippo, M.D. stated, "The company definitively knows the real identity of  '' and recognizes Matsuman709 to be highly credible and also an ideal 'third-party intermediary' for handling sensitive information from the public based on matsuman709's experience and proven skills.  The reality is that Matsuman709 is perfectly suited for a role of this kind that involves a very complex problem and quite a number of parties, including issues related to U.S. intelligence agencies which the company identified in its sourcing investigation of Shire's IPR a couple months ago.  That Matsuman709 does not want to be in the middle of this massive story as its main whistleblower makes Matsuman709 an optimal candidate to secure the interests of other whistleblowers from the public who would directly provide Matsuman709 sensitive information who, in turn, would safely package it for Lucerne Biosciences so the company can do its business."   Sanfilippo added, "Moreover, the company put Matsuman709 to a 'trust test' over the course of the week.  Needless to say, Matsuman709 passed it with flying colors and delivered more than expected.  Anyone can see it for themselves in this week's events in 'The Patent '813 Story, Part II,' in particular through Matsuman709's March 7 and March 10 emails to Nils Pratley of The Guardian and Jim Puzzanghera of the Los Angeles Times that bcc'd me and other key persons involved in the story."  

Lucerne Biosciences, LLC would encourage anyone with sensitive information of any kind related to "The Patent '813 Story" in any way (whether directly or indirectly), who wishes it be used to support truth and justice in the public interest, to pass it along electronically to "third-party intermediary" Matsuman709 at however its sender is most comfortable (i.e., alias email, etc.)   If there should be any doubt about doing so, simply look at the story's evidence to make your decision.

Additional Information/Related References

"The Patent '813 Story, Part II" (updated March 10, 2016 at 5 pm EST) available at: or at:

In Surprise Twist for "The Patent '813 Story," Lucerne Biosciences Asks the Global Public-At-Large "Who Is ' the Informant'?" and "What Could the Whistleblower 'Inside Information' Be All About?" available at: or in PDF at:

Media Contact: 
Louis Sanfilippo, Public Manager
Lucerne Biosciences, LLC

SOURCE Lucerne Biosciences, LLC